Curated News
By: NewsRamp Editorial Staff
October 22, 2026
NeuroThera Advances FDA-Approved Phase IIb Trial for Tourette Syndrome
TLDR
- NeuroThera's SCI-110 cleared a key manufacturing milestone, positioning the company to lead in cannabinoid-based Tourette Syndrome treatments with a first-mover advantage.
- The QP batch release authorizes shipment of SCI-110 to three clinical sites, enabling patient enrollment in the FDA-approved Phase IIb trial for Tourette Syndrome.
- NeuroThera's progress on SCI-110 offers hope for adults with Tourette Syndrome, addressing substantial unmet treatment needs and potentially improving quality of life.
- SCI-110 combines dronabinol and PEA in one oral dose, a novel approach now cleared for shipment to Yale, Hannover Medical School, and Tel Aviv Sourasky.
Impact - Why it Matters
This news matters because Tourette Syndrome affects millions worldwide, yet treatment options remain limited and often associated with significant side effects. The advancement of SCI-110 into Phase IIb clinical trials represents a potential new therapeutic approach for a condition with substantial unmet needs. If successful, SCI-110 could offer a novel cannabinoid-based treatment that improves quality of life for adults with TS. For investors, the progress de-risks the clinical program and brings NeuroThera closer to potential commercialization, which could create value for shareholders and attract partnership interest. Moreover, the involvement of prestigious clinical sites like Yale and Hannover Medical School underscores the scientific credibility of the study and may accelerate enrollment and data collection. Overall, this milestone signals growing momentum in the development of innovative CNS therapies and highlights the potential of cannabinoid-based medicines in addressing neurological disorders.
Summary
NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., has announced significant progress in its FDA-approved clinical trial program for SCI-110, a proprietary cannabinoid-based drug candidate for Tourette Syndrome (TS) in adults. The company has completed manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (QP), a key regulatory milestone that authorizes shipment of clinical trial material to participating study sites. This release enables site activation activities and supports the initiation of patient enrollment in the Phase IIb trial.
The Phase IIb clinical trial is being conducted at three sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All sites have successfully completed site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release. The completion of site initiation activities across all participating centers, together with the European QP release, marks a significant operational milestone for NeuroThera. The company is now advancing toward patient enrollment, with investigational product shipments expected in the near term.
SCI-110 combines dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form and is protected by patents. The Phase IIb study will evaluate the efficacy, safety, and tolerability of SCI-110 in adults with TS, a condition with substantial unmet treatment needs. NeuroThera Labs Inc. focuses on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. For further information, please visit www.sedarplus.ca or view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, NeuroThera Advances FDA-Approved Phase IIb Trial for Tourette Syndrome
